Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The immunotherapy developer, which counts Pfizer, Sanofi, Merck & Co, Eli Lilly, Amgen and Vertex Pharmaceuticals as early investors, has picked up $102m.

Personalised finance management service Albert secured $50m in a CapitalG-led round that included fellow corporate venturing vehicle American Express Ventures.

The antibody-based drug developer has now raised $210m altogether, with both SK Holdings and Legend Capital backing its series B-plus round.

The driverless delivery vehicle developer has added $28.8m to its coffers, the round being led by electric carmaker and existing backer Leading Ideal.

Humanised antibody-based drug developer Harbour BioMed has now raised $210m altogether following a series B-plus round featuring Zhejiang University Future Capital.

The TV and social media-focused talent agency received $25.7m from ByteDance and has formed a strategic partnership with the coprorate.

The healthcare access platform developer closed a series A round led by UnityPoint Health Ventures that included fellow corporate VC unit Well Ventures and ThedaCare.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.